Merieux Equity Partners
Mérieux Equity Partners is a leading European healthcare-specialized investment firm founded in 2009, managing over €1.6 billion in assets through two dedicated platforms: Innovation (venture capital) and Buyout (growth and buyout). The firm supports companies ranging from start-ups to established leaders across Europe and North America.
Key facts
Recent exits
Coverage notes
6 funds tracked, 53 portfolio companies (33 active · 20 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Merieux Equity Partners has raised, with its portfolio companies. Hand-checked from public filings.
Mérieux Innovation 2VC2024 · 2yr€380M4 active
Unrealized
4 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Corflow | Healthcare | Europe | 2024 |
| Curea Medical GmbH | Healthcare | Europe | 2025 |
| Health in Code | Healthcare | Europe | 2026 |
| Ona Therapeutics | Healthcare | Spain | 2026 |
Mérieux Participations 4Buyout2023 · 3yr€500M3 active
Unrealized
3 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biobest | Healthcare | Europe | 2022 |
| CEVA Santé Animale | Healthcare | Europe | 2025 |
| Piercan | Healthcare | Europe | 2023 |
Mérieux Participations 3Buyout2019 · 7yr€350M7 active · 2 realized
Unrealized
7 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Dental Monitoring | Healthcare | Europe | 2021 |
| Domus VI | Healthcare | Europe | 2021 |
| Elsan | Healthcare | Europe | 2020 |
| GTP Bioways | Healthcare | Europe | 2019 |
| Janvier Labs | Healthcare | Europe | 2022 |
| SERB Pharmaceuticals | Healthcare | Europe | 2021 |
| SWIXX BioPharma | Healthcare | Europe | 2021 |
Realized
2 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| DOC Generici | Healthcare | Europe | 2019 | 2022 | Trade Sale | – | |
| Plantex | Healthcare | Europe | 2020 | 2025 | Trade Sale | – |
Mérieux Innovation 1VC2014 · 12yr€120M15 active · 14 realized
Unrealized
15 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| AcuSurgical | Healthcare | Europe | 2021 |
| Amyl Therapeutics | Healthcare | Europe | 2021 |
| Broken String Biosciences | Healthcare | Europe | 2023 |
| Cairdac | Healthcare | Europe | 2022 |
| Cell-Easy | Healthcare | Europe | 2020 |
| Deepull | Healthcare | Europe | 2020 |
| InnoSyn | Healthcare | Europe | 2023 |
| Inscripta | Healthcare | US | 2018 |
| Keranova | Healthcare | Europe | 2016 |
| Mimetas | Healthcare | Europe | 2020 |
| MRM Health | Healthcare | Europe | 2020 |
| Neurinnov | Healthcare | Europe | 2021 |
| Prodigest | Healthcare | Europe | 2020 |
| SeqOne Genomics | Healthcare | Europe | 2022 |
| Triple Ring Technologies | Healthcare | US | 2020 |
Realized
14 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Advencis | Healthcare | Europe | 2012 | 2014 | Trade Sale | – | |
| Amplitude Systèmes | Healthcare | Europe | 2012 | 2019 | Trade Sale | – | |
| Ivantis | Healthcare | US | 2017 | 2022 | Trade Sale | – | |
| Kalila Medical | Healthcare | US | 2014 | 2016 | Trade Sale | – | |
| LabQuality | Healthcare | Europe | 2023 | 2025 | Trade Sale | – | |
| Mablink Bioscience | Healthcare | Europe | 2022 | 2023 | Trade Sale | – | |
| Mabtech | Healthcare | Europe | 2019 | 2024 | Trade Sale | – | |
| Origene | Healthcare | US | 2015 | 2016 | Trade Sale | – | – |
| Physioassist | Healthcare | Europe | 2017 | 2023 | Trade Sale | – | |
| Quantalife | Healthcare | Europe | 2010 | 2011 | Trade Sale | – | |
| Supersonic Imagine | Healthcare | Europe | 2010 | 2019 | Trade Sale | – | |
| TARA Biosystems | Healthcare | US | 2019 | 2022 | Trade Sale | – | |
| TWIST Bioscience | Healthcare | US | 2013 | 2020 | IPO | – | |
| XERIS Pharmaceuticals | Healthcare | US | 2017 | 2018 | IPO | – |
Mérieux Participations 2Buyout2014 · 12yr€200M4 active · 3 realized
Unrealized
4 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Nutragroup | Healthcare | Europe | 2018 |
| Seqens | Healthcare | Europe | 2016 |
| SGH Medical Pharma | Healthcare | Europe | 2018 |
| Theravia | Healthcare | Europe | 2018 |
Realized
3 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| KeepMED | Healthcare | Israel | 2015 | – | – | – | – |
| Laboratoires INELDEA | Healthcare | Europe | 2017 | 2021 | Trade Sale | – | |
| LNA Santé | Healthcare | Europe | 2016 | 2022 | Secondary | – |
Mérieux Participations 1Buyout2010 · 16yr€80M0 active · 1 realized
Realized
1 exit| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Lavorel Medicare | Healthcare | Europe | 2013 | 2019 | Trade Sale | – |
Saved GPs appear in your watchlist, one click from your workspace.
About Merieux Equity Partners
Mérieux Equity Partners is a leading European healthcare-specialised investment firm with €1.6 billion of assets under management as of December 2024, founded in 2009 and headquartered in Lyon. The firm operates through two dedicated platforms: Innovation (venture capital) and Buyout (growth and buyout), supporting the healthcare ecosystem across early-stage biotech innovation through to mid-cap healthcare buyout transactions, with the platform aligned with the broader Institut Mérieux life sciences industrial heritage.
Investment thesis
Mérieux Equity targets European and selectively North American healthcare companies across the development lifecycle, deploying dedicated venture commitments through the Innovation platform (early-stage biotech and HealthTech) plus growth and buyout equity through the Buyout platform (mid-cap healthcare services and products). Equity ticket sizes vary by strategy from venture-stage early commitments through to mid-cap healthcare growth equity positions. The exclusive healthcare sector focus enables deep clinical and regulatory expertise across portfolio companies.
Recent activity
Recent realised exits include Mabtech (healthcare, 2024), Mablink Bioscience (healthcare, 2023), Physioassist (healthcare, 2023), DOC Generici (healthcare, 2022) and Ivantis (healthcare, 2022), reflecting active distribution across the healthcare franchise. The platform tracks 6 funds, 34 active portfolio companies and 17 realised exits across the dual Innovation and Buyout programmes. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
France·€196.0BFrance·€52.8BFrance·€40.8BFrance·€33.0BFrance·€27.0BFrance·€13.2BFrance·€11.6BFrance·€9.0BFrance·€7.0BFrance·€6.7BFrance·€6.0BFrance·€5.1B